http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007110084-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ebe8f2f781a3c9a4cf92451d5a67e6cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4935577e3a2d1230cc4928bcc25c9d1d
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F1-005
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F1-08
filingDate 2006-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_503971bbbaa76ae516c313469a4c4adc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7b94b4d98f844e2ecaf005a41afff5b
publicationDate 2007-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2007110084-A1
titleOfInvention Pyrazinic acid copper (i) complex
abstract The present invention provides a process for the preparation of a complex of pyrazinic acid and copper (I) chloride, by dissolving the components in a polar solvent, e.g. water, ethanol, acetone and boiling, allowing the mixture to cool, and stand over several hours to yield the complex [CuCl (C4H5N2CO2) ].2H2O. The present invention provides methods for treatment of Fatigue, Infertility, Weakness of muscles, in human requiring such treatment, comprising administering to say a person, an anti-fatigue, etc., effective amount of the complex having the above formula or a pharmaceutical composition comprising the complex together with a pharmaceutically acceptable carrier, diluent and/or excipient. The concentration of the complex (main ingredient) in the pharmaceutical composition depends on. several factors, e.g. type and degree of disease, age of patient, damage of organ or organs.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9756079-B2
priorityDate 2006-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02070496-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135986745
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128590515
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID228292897
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1047
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18402047
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID67299335
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397196
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21226150
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393724
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54676860
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226397195
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID189460
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID67299332
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128707817
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID228292899

Total number of triples: 30.